Drug-interaction-induced rhabdomyolysis.
Segaert
M F
MF
Department of Medicine, H. Hartziekenhuis, Roeselare, Belgium.
De Soete
C
C
Vandewiele
I
I
Verbanck
J
J
D000368:Aged; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D017964:Itraconazole / Q000008:administration & dosage / Q000009:adverse effects*; D016030:Kidney Transplantation; D008148:Lovastatin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D008297:Male; D012206:Rhabdomyolysis / Q000139:chemically induced*; D019821:Simvastatin
D000924:Anticholesteremic Agents; D000935:Antifungal Agents; D007166:Immunosuppressive Agents; D017964:Itraconazole; D016572:Cyclosporine; D008148:Lovastatin; D019821:Simvastatin